Cytomorphology of Non-Small Cell Lung Carcinoma with MET Exon 14 Skipping Mutations

被引：0
|
作者：
Labiano, Tania [1 ]
Echegoyen, Ana [2 ]
Moneo, Marta [2 ]
Elizalde, Jesus [2 ]
Guerrero, David [2 ]
机构：
[1] Hosp Univ Navarra, Cizur Menor, Spain
[2] Complejo Hosp Navarra, Pamplona, Spain
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
349
引用
收藏
页码：S438 / S439
页数：2
相关论文
共 50 条
  • [21] Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer
    Li, Wen-Feng
    Kang, Jin
    Zhang, Xu-Chao
    Jian, Su
    Chen, Huajun
    Wang, Zhen
    Wang, Bin-Chao
    Zhou, Qing
    Tu, Hai-Yan
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC)
    Marks, Jennifer Aline
    Gandhi, Nishant
    Halmos, Balazs
    Ramalingam, Suresh S.
    Bazhenova, Lyudmila
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non -small cell lung cancer?
    Pruis, Melinda A.
    von der Thusen, Jan H.
    Dubbink, Hendrikus Jan
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (22)
  • [24] Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
    Wu, Yi-Long
    Smit, Egbert F.
    Bauer, Todd M.
    CANCER TREATMENT REVIEWS, 2021, 95
  • [25] Analysis of MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) by histology and specific mutation.
    Marks, Jennifer Aline
    Yin, Jun
    Halmos, Balazs
    Bazhenova, Lyudmila
    Ramalingam, Suresh S.
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress
    Paik, P.
    Sakai, H.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1046 - S1046
  • [27] MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
    Zheng, Difan
    Wang, Rui
    Ye, Ting
    Yu, Su
    Hu, Haichuan
    Shen, Xuxia
    Li, Yuan
    Ji, Hongbin
    Sun, Yihua
    Chen, Haiquan
    ONCOTARGET, 2016, 7 (27) : 41691 - 41702
  • [28] Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
    Brazel, Danielle
    Zhang, Shannon
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 33 - 45
  • [29] Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Zhang, Eric W.
    Lennerz, Jochen K.
    Heist, Rebecca S.
    CANCERS, 2019, 11 (12)
  • [30] Analysis of MET Exon 14 Skipping Mutations and MET Gene Amplifications in Non Small-Cell Lung Cancer Patients
    Salido, Marta
    Clave, Sergi
    Dalmases, Alba
    Pijuan, Lara
    Longaron, Raquel
    Lorenzo, Marta
    Taus, Alvaro
    Torres, Erica
    Rocha, Pedro
    Espinet, Blanca
    Bellosillo, Beatriz
    Arriola, Edurne
    MODERN PATHOLOGY, 2018, 31 : 749 - 749
12345